Tandem Diabetes Care (TNDM) Gains from Investment Securities (2013 - 2022)
Tandem Diabetes Care's (TNDM) quarterly Gains from Investment Securities came in at -$44000.0 in Q4 2022, down 237.5% YoY from $32000.0 in Q4 2021, and down 266.67% on a QoQ basis from -$12000.0 in Q3 2022.
Tandem Diabetes Care (TNDM) Gains from Investment Securities (2013 - 2022) Analysis & Trends
Tandem Diabetes Care (TNDM) has 6 years of Gains from Investment Securities data on file, last reported at -$44000.0 in Q4 2022.
- Quarterly Gains from Investment Securities fell 237.5% year-over-year to -$44000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$147000.0 (down 110.61% YoY) and the FY2022 annual result came in at -$147000.0, down 110.61% from the prior year.
- Gains from Investment Securities declined to -$44000.0 in Q4 2022, from -$12000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $42.5 million in Q2 2018 to a low of -$2.8 million in Q4 2020.
- A 5-year average of $4.8 million and a median of $332000.0 in 2021 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 3281.13% in 2020, down 1347.35% in 2020.
- Tracing TNDM's Gains from Investment Securities over 5 years: stood at -$2.5 million in 2018, then jumped by 108.87% to $226000.0 in 2019, then tumbled by 1347.35% to -$2.8 million in 2020, then soared by 101.14% to $32000.0 in 2021, then plunged by 237.5% to -$44000.0 in 2022.
- The last three Gains from Investment Securities figures came in at -$44000.0 (Q4 2022), -$12000.0 (Q3 2022), and -$57000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -44,000.00 |
| Dec 31, 2022 | -44,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Mar 31, 2022 | -34,000.00 |
| Mar 31, 2022 | -34,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Jun 30, 2021 | 272,000.00 |
| Jun 30, 2021 | 272,000.00 |
| Mar 31, 2021 | 690,000.00 |
| Mar 31, 2021 | 690,000.00 |
| Dec 31, 2020 | -2.82 Mn |
| Dec 31, 2020 | -2.82 Mn |
| Sep 30, 2020 | 3.65 Mn |
| Sep 30, 2020 | 3.65 Mn |